Braveheart Bio (BRVE) CEO Murdoch Travis Buys Stock & Receives Award

What Happened
Murdoch Travis, CEO, President and a director of Braveheart Bio (BRVE), made an open-market purchase of 83,333 shares at $18.00 per share on 2026-08-07 for a total of $1,499,994. He was also granted a derivative award of 550,000 shares (reported as an acquisition at $0.00) on 2026-08-05. The cash purchase is a direct buy (P code) and the 550,000 shares are an award/derivative grant (A code).

Key Details

• Purchase: 83,333 shares at $18.00 on 2026-08-07, total ~$1,499,994. (Open-market purchase, code P)
• Grant: 550,000 shares on 2026-08-05, reported at $0.00 (derivative award, code A)
• Shares owned after transaction: not specified in the filing.
• Vesting note (Footnote F2): the award vests 1/48th monthly, starting on the monthly anniversary of July 23, 2026, subject to continuous service.
• Beneficial ownership disclaimer (Footnote F1): the reporting person disclaims beneficial ownership of these securities except to the extent of any pecuniary interest.
• Filing timeliness: Form 4 filed 2026-08-07; the report covers transactions on 08-05 and 08-07 and was filed within the typical Section 16 reporting window (timely).

Context
The purchased shares were a straightforward open-market buy (cash outlay ≈ $1.5M), which is a direct purchase rather than a sale or cashless exercise. The 550,000-share award is a derivative grant with a multi-year monthly vesting schedule—these shares are not immediately fully owned or saleable and will vest over 48 months, subject to continued service. The filing includes the standard beneficial-ownership disclaimer and provides no additional details about post-transaction holdings.